- Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes
- Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024
- Topline results from the completed Phase I/II will be reported in the first half of 2024